RE:nr-- this makes it now clear the voucher $ is very near...And so what are your milestones as management has none except preclinical trials of drugs bought for $3.8M!? Regale us with your creative pumping machine predictions. Please dont say voucher cash and production jobs. You obviously dont know how incredibly dumb you sound when you post that stuff
tommyjones1 wrote: 2021 is only mentioned because management cant predict the future since time travel is still classified BUT...if u read the NR, the voucher cash will be in LMNL coffers before the closing of the deal, so real soon Stockbofoon.
FDA issue voucher has to be settled before closing of deal per NR friday. Can be announced anytime...
LAVAL, QC and CAMBRIDGE, England, July 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has closed on the previously announced divestment of its plasma-derived therapeutics manufacturing subsidiary to Kedrion S.p.A. ("Kedrion") (the "First Closing"). The manufacturing facility is operated through Liminal BioSciences' subsidiary, Prometic Bioproduction Inc. ("PBP").
The consideration received by Liminal for PBP was USD 5 million, which was received upon closing, subject to adjustments. Liminal will also be entitled to receive 70% of the net proceeds from a sale of the Rare Pediatric Disease Priority Review Voucher ("PRV") by its subsidiary, Prometic Biotherapeutics Inc. ("PBT"), which would be payable to Liminal prior to closing the divestment of its remaining plasma-derived therapeutics business operated through PBT (the "Second Closing"). PBT is the holder of the biological license application ("BLA") for Ryplazim® (plasminogen, human-tvmh) ("Ryplazim®") for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia). The Second Closing is subject to the fulfilment of certain conditions precedent, including the sale of the PRV by PBT.